EA202190709A1 - Универсальные донорские клетки - Google Patents

Универсальные донорские клетки

Info

Publication number
EA202190709A1
EA202190709A1 EA202190709A EA202190709A EA202190709A1 EA 202190709 A1 EA202190709 A1 EA 202190709A1 EA 202190709 A EA202190709 A EA 202190709A EA 202190709 A EA202190709 A EA 202190709A EA 202190709 A1 EA202190709 A1 EA 202190709A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mhc
universal donor
donor cells
encodes
genetic modification
Prior art date
Application number
EA202190709A
Other languages
English (en)
Inventor
Алиреза РЕЗАНИА
Тони У. Хо
Ребека Рамос-Зейес
Original Assignee
Криспр Терапьютикс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Криспр Терапьютикс Аг filed Critical Криспр Терапьютикс Аг
Publication of EA202190709A1 publication Critical patent/EA202190709A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В данном документе представлены генетически модифицированные клетки, которые совместимы со многими субъектами, например универсальные донорские клетки, и способы получения указанных генетически модифицированных клеток. Универсальные донорские клетки содержат по меньшей мере одну генетическую модификацию в пределах по меньшей мере одного гена, который кодирует один или несколько человеческих лейкоцитарных антигенов MHC-I или MHC-II или компонент или регулятор транскрипции комплекса MHC-I или MHC-II, или рядом с ним, по меньшей мере одну генетическую модификацию, которая обеспечивает повышение экспрессии по меньшей мере одного полинуклеотида, который кодирует толерогенный фактор, и необязательно по меньшей мере одну генетическую модификацию, которая обеспечивает повышение или снижение экспрессии по меньшей мере одного гена, который кодирует фактор выживания.
EA202190709A 2018-09-07 2019-09-07 Универсальные донорские клетки EA202190709A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862728529P 2018-09-07 2018-09-07
PCT/IB2019/057555 WO2020049535A1 (en) 2018-09-07 2019-09-07 Universal donor cells

Publications (1)

Publication Number Publication Date
EA202190709A1 true EA202190709A1 (ru) 2021-07-23

Family

ID=68165653

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190709A EA202190709A1 (ru) 2018-09-07 2019-09-07 Универсальные донорские клетки

Country Status (15)

Country Link
US (9) US20200080107A1 (ru)
EP (1) EP3847189B1 (ru)
JP (1) JP2021534806A (ru)
KR (1) KR20210075086A (ru)
CN (1) CN113423727A (ru)
AU (1) AU2019334208A1 (ru)
BR (1) BR112021004254A2 (ru)
CA (1) CA3111696A1 (ru)
CO (1) CO2021004223A2 (ru)
EA (1) EA202190709A1 (ru)
IL (1) IL281280A (ru)
MX (1) MX2021002645A (ru)
PH (1) PH12021550476A1 (ru)
SG (1) SG11202102266TA (ru)
WO (1) WO2020049535A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
US20200080107A1 (en) * 2018-09-07 2020-03-12 Crispr Therapeutics Ag Universal donor cells
MX2022002783A (es) 2019-09-05 2022-04-06 Crispr Therapeutics Ag Celulas donantes universales.
BR112022004031A2 (pt) 2019-09-05 2022-08-16 Crispr Therapeutics Ag Células doadoras universais
EP4159846A1 (en) * 2020-05-26 2023-04-05 Healios K.K. Hypoimmunogenic cells
AU2021353867A1 (en) * 2020-09-29 2023-05-11 NeuExcell Therapeutics Inc. Neurod1 combination vector
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
KR20230146007A (ko) * 2020-12-31 2023-10-18 크리스퍼 테라퓨틱스 아게 범용 공여자 세포
CN117083292A (zh) * 2021-04-02 2023-11-17 科济生物医药（上海）有限公司 Cs1工程化细胞及其组合物
US20230014010A1 (en) 2021-06-23 2023-01-19 Crispr Therapeutics Ag Engineered cells with improved protection from natural killer cell killing
CN113846063B (zh) * 2021-08-27 2022-11-29 浙江大学 一种适用于同种异体移植的通用型人源干细胞以及构建方法
KR20230131816A (ko) * 2022-03-04 2023-09-14 주식회사 툴젠 저면역원성 줄기세포, 줄기세포로부터 분화되거나 유래된 저면역원성 세포및 이의 제조방법
US20240010991A1 (en) * 2022-07-01 2024-01-11 Janssen Biotech, Inc. Materials and methods for bioengineered ipsc populations
WO2024003349A1 (en) 2022-07-01 2024-01-04 Novo Nordisk A/S Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
CN116732099B (zh) * 2023-08-07 2023-11-24 北赛泓升(北京)生物科技有限公司 一种干细胞多重CRISPR/Cas基因组编辑方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
US20060222633A1 (en) 2000-05-11 2006-10-05 Yale University Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host
US7432104B2 (en) 2001-08-06 2008-10-07 Bresgen Inc. Methods for the culture of human embryonic stem cells on human feeder cells
CN103898047B (zh) 2003-12-23 2020-03-03 维亚希特公司 定形内胚层
US8586357B2 (en) 2003-12-23 2013-11-19 Viacyte, Inc. Markers of definitive endoderm
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
US7541185B2 (en) 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
US20050266554A1 (en) 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
JP5102030B2 (ja) 2004-08-13 2012-12-19 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド ヒト胚性幹細胞における自己再生および分化のための組成物および方法
PL1957636T3 (pl) 2005-10-27 2018-12-31 Viacyte, Inc. Grzbietowa i brzuszna endoderma jelita przedniego wykazująca ekspresję pdx1
WO2007101130A2 (en) 2006-02-23 2007-09-07 Novocell, Inc. Compositions and methods useful for culturing differentiable cells
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
EP2650360B1 (en) 2006-03-02 2019-07-24 Viacyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
WO2007139929A2 (en) 2006-05-25 2007-12-06 The Burnham Institute For Medical Research Methods for culture and production of single cell populations of human embryonic stem cells
KR101617243B1 (ko) 2007-07-31 2016-05-02 라이프스캔, 인코포레이티드 인간 배아 줄기 세포의 분화
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US8623650B2 (en) 2007-10-19 2014-01-07 Viacyte, Inc. Methods and compositions for feeder-free pluripotent stem cell media containing human serum
US9062290B2 (en) 2007-11-27 2015-06-23 Lifescan, Inc. Differentiation of human embryonic stem cells
US8338170B2 (en) 2008-04-21 2012-12-25 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
US7939322B2 (en) 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm
US20120058105A1 (en) 2008-06-27 2012-03-08 Martin Kean Chong Ng Method of treatment of vascular complications
JP5785088B2 (ja) 2008-10-31 2015-09-24 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の膵内分泌系への分化
US9012218B2 (en) 2008-10-31 2015-04-21 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US8895300B2 (en) 2008-11-04 2014-11-25 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
US8008075B2 (en) 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
AU2009313870B2 (en) 2008-11-14 2013-07-11 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
WO2010124142A2 (en) 2009-04-22 2010-10-28 Cythera, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
JP5961110B2 (ja) 2009-04-27 2016-08-02 バイアサイト インク 低分子サポート多能性細胞成育およびその方法
SG177483A1 (en) 2009-07-20 2012-02-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
AR077766A1 (es) 2009-07-20 2011-09-21 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas
PL2516626T3 (pl) 2009-12-23 2017-10-31 Janssen Biotech Inc Różnicowanie ludzkich zarodkowych komórek macierzystych
RU2701335C2 (ru) 2009-12-23 2019-09-25 Янссен Байотек, Инк. Способ получения популяции панкреатических эндокринных клеток, соэкспрессирующих nkx6.1 и инсулин, и способ лечения диабета
KR101836850B1 (ko) 2010-08-31 2018-03-09 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
BR112013004614A2 (pt) 2010-08-31 2024-01-16 Janssen Biotech Inc Diferenciação de células-tronco pluripotentes
ES2690663T3 (es) 2010-12-08 2018-11-21 Viacyte, Inc. Agentes y métodos para inhibir el crecimiento de células madre pluripotentes humanas
WO2012145384A1 (en) 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
SG10201608914WA (en) 2011-12-22 2016-12-29 Janssen Biotech Inc Differentiation of human embryonic stem cells into single hormonal insulin positive cells
ES2615346T3 (es) 2012-04-25 2017-06-06 Deutsches Krebsforschungszentrum Inhibidores de la proteína que interacciona con tiorredoxina (TXNIP) para terapia
CA2872770A1 (en) 2012-05-07 2013-11-14 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endoderm
ES2960803T3 (es) 2012-05-25 2024-03-06 Univ California Métodos y composiciones para la modificación de ADN diana dirigida por RNA y para la modulación de la transcripción dirigida por RNA
BR112014030682A2 (pt) 2012-06-08 2017-06-27 Janssen Biotech Inc diferenciação de células tronco embrionárias humanas em células pancreáticas endócrinas
CN104603262A (zh) 2012-06-14 2015-05-06 詹森生物科技公司 使人胚胎干细胞分化为胰腺内分泌细胞
SG11201505119UA (en) 2012-12-31 2015-07-30 Janssen Biotech Inc Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
JP6557146B2 (ja) 2012-12-31 2019-08-07 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞から膵臓内分泌細胞膵臓内分泌細胞への分化のための、空気−液体界面での、ヒト胚性幹細胞の培養
RU2684215C2 (ru) 2012-12-31 2019-04-04 Янссен Байотек, Инк. Способ получения панкреатических эндокринных клеток (варианты) и способ увеличения выхода бета-клеток
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
SG11201509743WA (en) * 2013-06-03 2015-12-30 Theravectys Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence
DE112014002780T5 (de) 2013-06-11 2016-06-23 President And Fellows Of Harvard College SC-ß-Zellen und Zusammensetzungen und Verfahren zur Erzeugung der Zellen
KR20140144964A (ko) 2013-06-12 2014-12-22 한국생명공학연구원 티오레독신-결합 단백질을 유효성분으로 포함하는 약학적 조성물 및 이의 용도
JP2016534731A (ja) 2013-11-01 2016-11-10 ヤンセン バイオテツク，インコーポレーテツド 膵内分泌細胞への分化のためのヒト多能性幹細胞の懸濁及び集団化
MX2016015004A (es) 2014-05-16 2017-06-27 Janssen Biotech Inc Uso de moleculas pequeñas para mejorar la expresion de mafa en celulas endocrinas pancreaticas.
WO2016073955A2 (en) * 2014-11-06 2016-05-12 President And Fellows Of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
MX2017008176A (es) 2014-12-19 2018-02-09 Janssen Biotech Inc Cultivo en suspension de celulas madre pluripotentes.
JP2018515139A (ja) * 2015-05-08 2018-06-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 万能ドナー幹細胞および関連する方法
ES2953925T3 (es) 2015-11-04 2023-11-17 Fate Therapeutics Inc Ingeniería genómica de células pluripotentes
EP3500670A4 (en) 2016-08-17 2020-08-19 The Broad Institute, Inc. NEW CRISPR SYSTEMS AND ENZYMES
US9982267B2 (en) * 2016-10-12 2018-05-29 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
CA3042495A1 (en) 2016-11-10 2018-05-17 Viacyte, Inc. Pdx1 pancreatic endoderm cells in cell delivery devices and methods thereof
US20190376045A1 (en) 2017-01-13 2019-12-12 The Regents Of The University Of California Immunoengineered pluripotent cells
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
MX2020004444A (es) 2017-10-19 2020-07-22 Cellectis Integracion genica direccionada de genes de inhibidores de nk para terapia con celulas inmunes mejorada.
US20190223416A1 (en) 2018-01-23 2019-07-25 Cotyledon, LLC Canine genome editing
US20200080107A1 (en) 2018-09-07 2020-03-12 Crispr Therapeutics Ag Universal donor cells
KR20230146007A (ko) * 2020-12-31 2023-10-18 크리스퍼 테라퓨틱스 아게 범용 공여자 세포

Also Published As

Publication number Publication date
CO2021004223A2 (es) 2021-07-30
CN113423727A (zh) 2021-09-21
US10724052B2 (en) 2020-07-28
US20210348188A1 (en) 2021-11-11
US20230193313A1 (en) 2023-06-22
PH12021550476A1 (en) 2021-11-22
IL281280A (en) 2021-04-29
WO2020049535A1 (en) 2020-03-12
BR112021004254A2 (pt) 2021-05-25
US20200347411A1 (en) 2020-11-05
JP2021534806A (ja) 2021-12-16
AU2019334208A1 (en) 2021-03-18
KR20210075086A (ko) 2021-06-22
US11008586B2 (en) 2021-05-18
US11008587B2 (en) 2021-05-18
SG11202102266TA (en) 2021-04-29
US20230250448A1 (en) 2023-08-10
US20200347403A1 (en) 2020-11-05
EP3847189A1 (en) 2021-07-14
US20200080107A1 (en) 2020-03-12
MX2021002645A (es) 2021-06-23
US10865424B2 (en) 2020-12-15
US20210115471A1 (en) 2021-04-22
US20220064667A1 (en) 2022-03-03
US11180776B1 (en) 2021-11-23
CA3111696A1 (en) 2020-03-12
EP3847189B1 (en) 2024-05-22
US20200080114A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
EA202190709A1 (ru) Универсальные донорские клетки
MX2022002783A (es) Celulas donantes universales.
MX2022002663A (es) Celulas donantes universales.
WO2020168317A8 (en) Universal donor stem cells and related methods
WO2018064594A3 (en) Hla class i-deficient nk-92 cells with decreased immunogenicity
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
CY1123730T1 (el) Εμφυτευση βλαστικων κυτταρων με εναν συνδυασμο ενος παραγοντα που στοχευει βλαστικα κυτταρα και ρυθμιση ανοσορυθμιστικης σηματοδοτησης
PH12018550156A1 (en) Immunocompetent cell and expression vector expressing regulatory factors of immune function
MX2023005612A (es) Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
WO2016073955A3 (en) Cells lacking b2m surface expression and methods for allogeneic administration of such cells
WO2017160717A3 (en) Method of treating diseases using kinase modulators
AR102538A1 (es) Métodos de selección de la línea celular t y donante de la misma para la terapia adoptiva celular
WO2020099352A3 (en) Immunogenic peptides with new oxidoreductase motifs
AU2016335217A8 (en) Antigen receptors and uses thereof
MX2021006393A (es) Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
PH12016501689B1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
CO2022004603A2 (es) Inmunoterapia con anticuerpos biespecíficos de células car
WO2020092743A3 (en) Methods of treating diseases using kinase modulators
TR201901466T4 (tr) Opti̇mi̇ze edi̇lmi̇ş feli̇n lösemi̇ vi̇rüsü zarf geni̇ni̇ i̇çeren rekombi̇nant feli̇n lösemi̇ vi̇rüsü
EA202192264A1 (ru) Универсальные донорские стволовые клетки и соответствующие способы
MX2019010941A (es) Receptores de antigeno y usos de los mismos.
EA202090990A1 (ru) Системы и способы получения в-клеток генетически модифицированных для экспрессии выбранных антител
Чубань et al. PECULIARITIES OF MATERIAL LOSSES REPARATION TO VICTIMS OF EMERGENCIES
WO2015175599A3 (en) Immunotherapy with binding agents
TWD199605S (zh) 容器之部分